Comparing PolyPid (NASDAQ:PYPD) and LENSAR (NASDAQ:LNSR)

LENSAR ( NASDAQ:LNSR – Get Your Free Report ) and PolyPid ( NASDAQ:PYPD – Get Your Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Insider and institutional ownership

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 38.5% of LENSAR shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and big money managers believe a company is poised for long-term growth.

Rating and Earnings

This table compares LENSAR and PolyPid’s revenue, earnings per share (EPS) and valuation.

LENSAR has higher revenue and earnings than PolyPid. LENSAR is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Analyst recommendations

This is a summary of recent recommendations for LENSAR and PolyPid as reported by MarketBeat.com.

LENSAR currently has a consensus target price of $8.00, suggesting a potential upside of 75.82%. PolyPid has a consensus target price of $14.00, suggesting a potential upside of 288.89%. Given PolyPid’s higher possible upside, analysts plainly believe PolyPid is more favorable than LENSAR.

Risk and volatility

LENSAR has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

return

This table compares LENSAR and PolyPid’s net margins, return on equity and return on assets.

Summary

LENSAR beats PolyPid on 7 of the 11 factors compared between the two stocks.

About LENSAR

(Get a free report)

LENSAR, Inc., a commercial-stage medical device company, is focused on the design, development and commercialization of a femtosecond laser system for the treatment of cataracts and the management of preexisting or surgically induced corneal astigmatism. It offers the LENSAR Laser System which incorporates a range of patented technologies designed to help the surgeon achieve visual outcomes, efficiency and reproducibility through imaging, procedure planning, design and precision. The company also offers the ALLY Adaptive Cataract Treatment System, a design platform for femtosecond laser technology features improved laser capabilities in a single small unit that allows surgeons to perform a femtosecond laser-assisted cataract procedure in a single operating room. LENSAR, Inc. was founded in 2004 and is headquartered in Orlando, Florida.

About PolyPid

(Get a free report)

PolyPid Ltd., a clinical-stage biopharmaceutical company developing targeted, topical, and sustained-release therapies using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for the prevention of surgical site infections (SSI) in patients undergoing large-incision abdominal colorectal surgery. It is also developing OncoPLEX, for the treatment of intratumoral cancer. PolyPid Ltd. was established in 2008 and is headquartered in Petah Tikva, Israel.

Get news and reviews for LENSAR Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LENSAR and related companies with MarketBeat.com ‘s FREE daily email newsletter.